CagriSema FDA approval is one of the most-watched decisions in the GLP-1 world right now, and for good reason: it would be the first weight-loss medication to combine a GLP-1 with an amylin analogue. Novo Nordisk filed its application in December 2025, and the company says it expects the FDA’s answer in the last three months of 2026. Here is what CagriSema is, what the trials actually showed (including the head-to-head it lost to Zepbound), what it might cost, and how to think about it if you are already on a GLP-1.
What is CagriSema?
CagriSema is a once-weekly injection that pairs two active ingredients in one pen:
- Semaglutide (2.4 mg), the GLP-1 receptor agonist already sold as Wegovy and Ozempic. It slows digestion, blunts appetite and quiets food noise.
- Cagrilintide (2.4 mg), a long-acting amylin analogue. Amylin is a hormone released alongside insulin that signals fullness, so cagrilintide adds a second satiety pathway on top of the GLP-1 effect.
In trials, the two drugs were stepped up together over 16 weeks (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg of each), which is the same titration rhythm Wegovy users already know. If you have been on semaglutide, the first months on CagriSema would feel familiar.
CagriSema FDA approval timeline: where things stand
The CagriSema FDA approval process started on December 18, 2025, when Novo Nordisk announced it had submitted a New Drug Application for chronic weight management, based on the REDEFINE 1 and REDEFINE 2 trials. A standard FDA review runs about ten months from filing, which is why Novo guides to a decision in the fourth quarter of 2026. As of mid-October 2026, no decision has been announced, no PDUFA date has been made public, and no brand name has been revealed. The application covers weight management only; Novo has not yet filed for a type 2 diabetes indication.
Three outcomes are possible when the review ends. The FDA can approve CagriSema, issue a complete response letter asking for more data, or extend the review. For context, the other big pipeline drugs are on different clocks: Lilly’s oral Foundayo (orforglipron) is already approved, while retatrutide FDA approval is not expected until late 2027 or 2028. CagriSema would land in between, as the first new injectable since Zepbound.
What the REDEFINE trials showed
CagriSema’s phase 3 program is called REDEFINE. Here are the results that matter most for everyday users:
- REDEFINE 1 (adults with obesity, no diabetes): about 20.4% average weight loss at 68 weeks versus 3% on placebo. The often-quoted 22.7% figure assumes everyone stayed on the drug for the whole study.
- REDEFINE 2 (adults with obesity and type 2 diabetes): about 13.7% weight loss at 68 weeks versus 3.4% on placebo (15.7% in the if-everyone-adhered analysis).
- REIMAGINE 5 (type 2 diabetes, September 2026): a low 1 mg/1 mg dose of CagriSema produced about 12.4% weight loss at 60 weeks versus 9.1% on tirzepatide 5 mg, with similar A1C reductions.
- Beyond the scale: REDEFINE 1 participants saw meaningful drops in blood pressure, and follow-up analyses in 2026 reported reduced visceral fat and lower food cravings on brain imaging.
Those are strong numbers. They comfortably beat Wegovy alone (about 15% in STEP 1) and sit close to the tirzepatide range. If you want to see how different percentages translate to your own starting weight, the free GLP-1 weight loss calculator lets you compare them side by side.
The head-to-head with Zepbound
The result that cooled some of the CagriSema FDA approval excitement came in February 2026. REDEFINE 4 compared full-dose CagriSema (2.4 mg/2.4 mg) directly with the top 15 mg dose of tirzepatide (Zepbound) in 809 adults over 84 weeks. Tirzepatide won: 25.5% weight loss versus 23% for people who stayed on treatment, and 23.6% versus 20.2% when everyone was counted. CagriSema missed its goal of proving it was at least as effective as tirzepatide.
That matters for expectations, not for the approval itself. REDEFINE 4 was not part of the FDA filing, and the FDA approves drugs based on whether they are safe and effective against placebo, not on whether they beat a competitor. Still, it means CagriSema is likely to arrive as a close second to Zepbound on raw weight loss, which is more in line with our Zepbound vs Wegovy comparison than a leapfrog over it.
Side effects reported so far
CagriSema’s side-effect profile looks like a slightly stronger version of what semaglutide users already know. In REDEFINE 1, roughly 80% of people on CagriSema reported at least one digestive side effect, compared with about 40% on placebo. The usual suspects were nausea, constipation, vomiting, diarrhea and abdominal pain. Most were mild to moderate, clustered around dose increases, and faded over time. About 6% of participants stopped the drug because of side effects.
If you have managed GLP-1 nausea or GLP-1 constipation before, the same playbook applies: smaller meals, more fluids, more fiber and a slower titration if your prescriber agrees. Long-term and rarer risks are still being studied, as with any new medication.
What CagriSema could cost
Novo Nordisk has not announced a price, and it will not until CagriSema FDA approval is in hand. Two things are worth knowing while you wait. First, Novo’s own branded semaglutide currently runs about $349 a month for standard self-pay doses through its direct channels, and a combination product with a second active ingredient is unlikely to launch below that. Second, insurance coverage for weight-loss medication is tightening in many employer plans for 2027, and a brand-new drug typically faces prior authorization or a step-therapy requirement (try Wegovy or Zepbound first) before plans add it. Our GLP-1 cost guide covers how those rules work today.
One warning: products sold online as “compounded CagriSema” are not the real thing. The FDA has stated that cagrilintide cannot legally be used in compounding, and these products have not been reviewed for safety. If you see one advertised, that is a reason to walk away.
Should you wait for CagriSema FDA approval?
This is a conversation for you and your prescriber, but the data point in a clear direction. If a current GLP-1 is working for you and you tolerate it well, there is no evidence that switching to CagriSema would add much. If you are plateaued on Wegovy or want more than semaglutide alone delivers, Zepbound is available now and posted higher numbers in the only direct comparison. Where CagriSema may be most interesting is for people who respond well to semaglutide but want an extra push, or who cannot take tirzepatide for insurance or tolerance reasons.
Whatever you decide, keep your records tidy during the wait. Dose dates, weight trend, side effects and non-scale wins are exactly what your prescriber will want to see before approving a change, and you can track all of it free with Pep. Having a clean six-month history makes any switch conversation faster.
If you do switch: how to track the transition
When a new medication launches, the first few weeks are where tracking earns its keep. Log your last dose of the old medication and your first dose of the new one, so the gap between them is clear. Note every side effect with the date and dose, because the titration steps are where most of them appear. Weigh in on a consistent schedule rather than daily, and let the trend line do the talking. If you are moving from a pill like Foundayo or the Wegovy pill back to a weekly injection, set a weekly reminder from day one; it is the easiest habit to lose after months of daily pills.
CagriSema FDA approval FAQ
When will the FDA approve CagriSema?
Novo Nordisk expects a decision in the fourth quarter of 2026 (October to December). The FDA has not published a target date, and reviews can be extended, so treat this as an estimate rather than a promise. We will update this post the day a decision is announced.
Is CagriSema better than Zepbound?
Not on weight loss, based on the only head-to-head trial. In REDEFINE 4, tirzepatide 15 mg produced about 25.5% weight loss versus 23% for CagriSema over 84 weeks. CagriSema did beat a low dose of tirzepatide in people with type 2 diabetes in REIMAGINE 5, so results depend on dose and population.
Will CagriSema be covered by insurance after FDA approval?
Probably not right away. New weight-loss medications usually spend months going through formulary reviews, and most plans will require prior authorization or a trial of an existing GLP-1 first. Medicare’s Part D coverage for obesity medication is also limited to specific programs. Check with your plan after approval rather than assuming coverage.
For the primary sources behind this article, see Novo Nordisk’s REDEFINE 4 announcement and Healthline’s CagriSema overview.
Download Pep free — track your shots, pills & progress in one app.
This article is for educational purposes only and is not medical advice. Talk with your prescriber before starting, stopping or switching any medication.